Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - Palma, D A; Olson, R; Harrow, S (Lancet, 2019)
(10185):